ReviewDrug design, development and therapy2022

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.

Maria Napolitano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.